Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial.
Jay B LuskLáShauntá GloverSamir SonejiChristopher B GrangerEmily O'BrienNeha Pagidipati
Published in: American heart journal (2024)
Approximately 4.5 million adults in the U.S. are forecasted to be eligible for semaglutide 2.4mg SC weekly therapy, with substantial impact on CVD and mortality if accessible and broadly used.